ArticleJournal of pharmaceutical health care and sciences2026
Details of oral anticancer drug prescription audits by community pharmacists: a retrospective analysis of prescription inquiries.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer pharmacotherapy has shifted to outpatient settings, making community pharmacists essential for ensuring medication safety. Although community pharmacist prescription audits are important, evidence regarding the clinical significance of their prescription audits for oral anticancer agents remains limited. This study aimed to analyze the content of inquiries regarding oral anticancer drugs and clarify the details of prescription audits conducted by community pharmacists.
methodsThis single-institution retrospective a descriptive observational study included all records of inquiries regarding oral anticancer drugs submitted from community pharmacies to the National Cancer Center Hospital East between September 2023 and March 2025. Inquiry content was categorized based on treatment efficacy and safety concerns, while the level of pharmacist intervention was assessed based on the severity of the medication error and the clinical value of the pharmacist service. As the purpose of this study is to investigate prescription audits by community pharmacies, interventions unrelated to prescription auditing, such as telephone follow-ups or tracing reports, were excluded.
resultsDuring the study period, 184,688 prescriptions were issued, of which 384 inquiries (0.2%) involved oral anticancer agents and were included in the analysis. Prescription modifications occurred in 295 cases (77%). The most common inquiry categories were incorrect treatment duration (23%), adjustment for leftover medication (20%), and dosage errors (16%). Overall, 49% of cases were classified as potentially lethal, serious, or significant medication-order errors, and 49% were assessed as having a value of service of significant or higher. High-severity and high-value interventions most frequently involved errors in treatment duration and dosage.
conclusionsPrescription inquiries regarding oral anticancer agents frequently identified clinically significant prescribing issues, and community pharmacists provided high-value interventions. These findings indicate that community pharmacists play a crucial role in conducting high-quality prescription audits and enhancing the safety of outpatient cancer drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.